Skip to main content

Table 3 Unadjusted risk of hospitalization due to heart failure with DPP-4 inhibitors versus GLP-1 agonists in propensity score matched analyses

From: Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Cohort Medications No. of patients Person-years No. of HF events Crude incidence per 1000 person-years
Overall (primary analysis) DPP-4 inhibitors 160,803 76,749 5714 74
GLP-1 agonists 160,803 70,469 6098 87
Baseline HF
 Absent DPP-4 inhibitors 158,543 75,545 5533 73
GLP-1 agonists 158,543 69,682 5870 84
 Present DPP-4 inhibitors 1937 686 194 283
GLP-1 agonists 1937 739 212 287
Baseline CVD
 Absent DPP-4 inhibitors 132,047 62,552 3204 51
GLP-1 agonists 132,047 58,366 3487 60
 Present DPP-4 inhibitors 28,085 13,544 2579 190
GLP-1 agonists 28,085 11,835 2579 218
Individual drugs
 Saxagliptin Saxagliptin 49,214 19,302 1335 69
GLP-1 agonists 49,214 20,741 2058 99
 Sitagliptin Sitagliptin 160,609 81,573 6108 75
GLP-1 agonists 160,609 70,441 6239 89
  1. CI confidence interval, CVD cardiovascular diseases, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, HF heart failure, HR hazard ratio